You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel Cannabinoid Receptor Agonists as Analgesics

    SBC: ADOLOR CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition that is undertreated because because of the dose-limiting side effects of currently used therapeutics. Agonists at the cannabinoid (CB) receptors, including delta-9-tetrahydrocannabinol, have been shown to relieve pain in humans, but their use has been limited due to their psychotr ...

    SBIR Phase I 2001 Department of Health and Human Services
  2. Discovery of K Opioid Analgesics Using Chimeric Receptor

    SBC: ADOLOR CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition that is under treated because of the dose limiting side effects of currently used opiate therapeutics including respiratory depression, constipation, nausea, and physical dependence at therapeutic doses. Although arylacetamide K opioid agonists do not cause these side effects, they produc ...

    SBIR Phase I 2001 Department of Health and Human Services
  3. Novel Antagonists of the ORL-1 Receptor

    SBC: ADOLOR CORPORATION            Topic: N/A

    N/A

    SBIR Phase I 2001 Department of Health and Human Services
  4. Novel Antagonists of the ORL-1 Receptor

    SBC: ADOLOR CORPORATION            Topic: N/A

    N/A

    SBIR Phase II 2001 Department of Health and Human Services
  5. Enhancing the immunogenicity of idiotypes for therapy of Non-Hodgkin's lymphoma

    SBC: ADVAXIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Non-Hodgkin's Lymphoma (NHL) is characterized by an indolent clinical course with a median survival of 6- 10 years. The incidence of NHL in the US increases by about 2.5% per year. Clearly, there is a national need for improved therapies for this malignancy. Idiotype-based clinical trials for minimal residual disease of follicular NHL have shown increased disea ...

    STTR Phase I 2006 Department of Health and Human Services
  6. PEG-MODIFIED ENZYMES FOR IN-VIVO DECON OF OP TOXINS

    SBC: AGENTASE LLC            Topic: N/A

    DESCRIPTION ( Investigator's Abstract): Agentase, LLC seeks Small Business Innovation Research funding to determine the feasibility of using chemically modified enzymes for the treatment and prevention of organophosphorus poisonings. Several known enzymes exhibit hydrolytic activity on target organophosphorus compounds including nerve agent, chemical weapons ...

    SBIR Phase I 2001 Department of Health and Human Services
  7. PEG-MODIFIED ENZYMES FOR IN-VIVO DECON OF OP TOXINS

    SBC: AGENTASE LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Agentase, LLC seeks follow-on Phase II Small Business Innovation Research funding to develop prototype formulations of chemically modified enzymes for the treatment and, more importantly, the prevention of organophosphorus poisonings. Several known enzymes exhibit hydrolytic activity on target organophosphorus compounds including nerve agent chemical weapons su ...

    SBIR Phase I 2002 Department of Health and Human Services
  8. PEG-MODIFIED ENZYMES FOR IN-VIVO DECON OF OP TOXINS

    SBC: AGENTASE LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Agentase, LLC seeks follow-on Phase II Small Business Innovation Research funding to develop prototype formulations of chemically modified enzymes for the treatment and, more importantly, the prevention of organophosphorus poisonings. Several known enzymes exhibit hydrolytic activity on target organophosphorus compounds including nerve agent chemical weapons su ...

    SBIR Phase II 2002 Department of Health and Human Services
  9. Selective Inhibitors of Pancreatic Cholesterol Esterase

    SBC: ALBUQUERQUE AVIAN EXOTIC            Topic: N/A

    DESCRIPTION (Scanned from the Applicant's Abstract): The specific aim of this esterase (CE) inhibitor in an acute cholesterol absorption assay. Hamsters will be gavage fed 3H-labeled cholesterol with CE-inhibitor ranging from 20-200 umoles. Twenty-four hours later, hepatic and serum cholesterol absorption will be assayed. Hepatic and serum cholesterol levels will be det ...

    SBIR Phase I 2001 Department of Health and Human Services
  10. Simulating Residential Segregation Dynamics: Phase I

    SBC: Amber Waves Software            Topic: N/A

    Ethnic residential segregation is an enduring feature of American cities. Residential location and neighborhood context are important results that affect the life chances of individuals, families, and groups. Ethnic segregation is widely studied in college courses focusing on minority groups, poverty, social problems, and urban areas. Two problems hinder undergraduate students' ability to understa ...

    SBIR Phase I 2001 Department of Health and Human Services
US Flag An Official Website of the United States Government